Nucleotide Excision Repair

Nucleotide Excision Repair (NER) is the DNA repair pathway responsible for correcting bulky, helix-distorting DNA lesions — most notably ultraviolet radiation-induced pyrimidine dimers and chemical adducts that significantly disrupt the DNA double helix's normal structure — through a mechanism that excises a short stretch of nucleotides surrounding the lesion and resynthesizes the removed sequence using the intact complementary strand as template. It complements base excision repair by addressing a structurally distinct category of damage, one defined by helical distortion rather than a single chemically modified base.

The Category of Lesions NER Addresses

Helix-Distorting Bulky Adducts

Unlike the single, chemically modified but structurally minor lesions addressed by base excision repair, NER targets lesions that significantly distort the DNA double helix's normal geometry — cyclobutane pyrimidine dimers and 6-4 photoproducts caused by ultraviolet light being the archetypal examples, alongside bulky chemical adducts formed by various environmental carcinogens and certain chemotherapeutic agents.

Why Distortion Rather Than Chemistry Defines the Substrate

NER's lesion recognition machinery is fundamentally structure-sensing rather than chemistry-sensing, in contrast to the highly specific, lesion-type-matched glycosylases of base excision repair — this structural, rather than chemical, basis for recognition is what allows NER to address a remarkably broad and chemically diverse range of bulky lesions through a single shared recognition and excision mechanism.

The Two Distinct Sub-Pathways of NER

Global Genome NER

Global genome NER (GG-NER) surveys the genome broadly, independent of transcriptional activity, using the XPC-RAD23B complex (assisted by DDB1-DDB2 for certain lesion types, particularly UV photoproducts) to detect helix distortion anywhere in the genome, providing baseline surveillance and repair coverage across both transcribed and non-transcribed DNA.

Transcription-Coupled NER

Transcription-coupled NER (TC-NER) is triggered specifically when RNA polymerase II stalls at a lesion during active transcription, recruiting CSA and CSB proteins to initiate repair preferentially at the transcribed strand of actively expressed genes — this pathway provides more rapid, prioritized repair of lesions that would otherwise block gene expression, reflecting the particular cellular cost of leaving a transcription-blocking lesion unrepaired in an actively used gene.

The Core NER Mechanism Following Lesion Recognition

Verification and Unwinding

Following initial lesion detection by either sub-pathway, the TFIIH complex, containing the XPB and XPD helicases, unwinds the DNA around the lesion and verifies that genuine helix-distorting damage is present, providing a proofreading step that reduces the likelihood of the machinery proceeding on a false-positive detection.

Dual Incision and Excision

Once damage is verified, the structure-specific endonucleases XPG and ERCC1-XPF make incisions on either side of the lesion, releasing a short single-stranded DNA fragment — typically around twenty-four to thirty-two nucleotides in humans — containing the damaged bases, leaving a gap in the damaged strand flanked by the intact, undamaged complementary strand.

Gap-Filling Resynthesis and Ligation

DNA polymerase δ or ε, using the same replication accessory factors employed during normal genome replication (including PCNA), fills the resulting gap using the intact complementary strand as template, after which DNA ligase seals the remaining nick, completing restoration of the original, undamaged double helix sequence.

Clinical Syndromes Illustrating NER's Importance

Xeroderma Pigmentosum

Inherited loss-of-function mutations in any of several core NER genes (including XPA through XPG) cause xeroderma pigmentosum, a condition characterized by extreme sensitivity to ultraviolet light and a dramatically elevated risk of skin cancer, providing direct, clinically unambiguous evidence for NER's essential role in protecting against UV-induced DNA damage and its cancer-promoting consequences when that protection is absent.

Cockayne Syndrome and Related Disorders

Mutations specifically affecting CSA or CSB, disrupting transcription-coupled NER while leaving global genome NER comparatively intact, cause Cockayne syndrome, a distinct clinical presentation emphasizing developmental and neurological features over skin cancer risk — illustrating that GG-NER and TC-NER, while mechanistically overlapping downstream of lesion recognition, serve at least partially distinguishable biological roles whose selective loss produces different clinical consequences.

Relevance to Cancer Genome Instability and Treatment

UV Signature Mutations as a Diagnostic Feature

Tumors arising in NER-deficient contexts, or tumors from UV-exposed tissue with a high burden of unrepaired UV damage, display a characteristic mutational signature dominated by C-to-T transitions at dipyrimidine sites, providing a recognizable genomic fingerprint that reflects the specific type of unrepaired damage NER would otherwise have corrected.

NER and Platinum-Based Chemotherapy Response

Because certain platinum-based chemotherapeutic agents create bulky DNA adducts recognized and repaired by NER, a tumor's NER capacity directly influences its sensitivity to these agents — cancer cells with reduced NER function often show heightened sensitivity to platinum-based treatment, since they are less able to repair the therapeutically induced DNA damage before it triggers cell death, making NER pathway status a factor of interest in predicting and understanding chemotherapy response.

ERCC1 as a Biomarker

Expression levels of ERCC1, a core NER incision component, have been investigated as a predictive biomarker for platinum chemotherapy response across several cancer types, reflecting the direct mechanistic link between NER capacity and a tumor's ability to repair and thereby tolerate platinum-induced DNA damage.

Practical Significance

Nucleotide Excision Repair provides essential protection against bulky, helix-distorting DNA damage — most notably ultraviolet-induced photoproducts — through a structurally distinct recognition and excision mechanism from base excision repair, operating via two complementary sub-pathways addressing genome-wide and transcription-coupled repair needs respectively. Its clinical significance spans direct cancer predisposition syndromes arising from its inherited deficiency, characteristic mutational signatures left behind when its function is compromised, and its direct mechanistic relevance to predicting response to platinum-based chemotherapy agents that exploit the same bulky-adduct damage NER is specifically equipped to repair.